226 Direct-to-Consumer Advertising in Oncology T he O ncologist ® References 1 Wilkes MS, Bell RA, Kravitz RL. Direct-to-consumer prescription drug advertising: trends, impact, and implications. Health Aff (Millwood) 2000;19:110–128. 2 Melillo W. Drug companies work to stave off legislation. Adweek, July 11, 2005. 3 Lenzer J. FDA investigates direct to consumer adverts. BMJ 2005;331:1102. 4 Behrman RE. The Impact of Direct-to-Consumer Drug Advertising on Seniors’ Health and Health Care Costs. Testimony Before the Senate Special Committee on Aging. United States Senate, September 29, 2005. Available at http://aging.senate.gov/public/_files/hr148rb.pdf. Accessed December 15, 2005. 5 Fintor L. Direct-to-consumer marketing: how has it fared? J Natl Cancer Inst 2002;94:329–331. 6 Saul S. Dr ug ma kers to pol ice consumer ca mpa igns. T he New York Times, August 3, 2005:7. 7 Macilwain C. Drug firms back-pedal on direct advertising. Nature 2005;436:910–911. 8 CURE Magazine Media Kit. Available at http://www.curetoday.com/ advertising/documents/mediakit_11.14.05.pdf. Accessed December 15, 2005. 9 Lyles A. Direct marketing of pharmaceuticals to consumers. Annu Rev Public Health 2002;23:73–91. 10 U.S. Department of Health and Human Services. Guidance for Industry. Consumer-Directed Broadcast Advertisements. August 1999. Available at http://www.fda.gov/cder/guidance/1804fnl.pdf. Accessed December 15, 2005. 11
This is the end of the preview.
access the rest of the document.
Prescription drug, U.S. Department of Health and Human Services, Direct-to-consumer advertising, Direct-to-consumer prescription drug